MedicalDevices

FDA Officer Overseeing Musk's Neuralink Devices Terminated Amid Controversy

1 month ago

In a surprising turn of events, the U.S. Food and Drug Administration (FDA) has terminated an official who played a crucial role in overseeing Neuralink, the neurotechnology company founded by Elon Musk. The dismissal has raised eyebrows and concerns about the ongoing regulatory scrutiny that Neuralink faces as it aims to develop cutting-edge brain-computer interface devices.

Kestra Files for IPO Amidst Market Buzz and Future Aspirations

2 months ago

Kestra, a leading medical device company backed by Bain Capital and Endeavour, has officially filed for an initial public offering (IPO). This move comes at a significant time in the healthcare sector, as the demand for innovative medical technologies continues to surge. The company has positioned itself as a strong player in the industry, focusing on developing advanced medical solutions that cater to a wide range of healthcare needs.

EU Investigation Uncovers Discriminatory Practices in Chinese Medical Device Procurement

3 months ago

In a recent report released by the European Union, evidence has emerged indicating that Chinese authorities are systematically discriminating against foreign suppliers in the procurement of medical devices. This investigation highlights a growing concern among European nations regarding unequal trade practices and market access issues in China, particularly in the healthcare sector, which is critical in the context of global health and economic recovery.

Stryker to Acquire Inari Medical in Major $80 per Share Deal

3 months ago

In a significant development within the medical device sector, Stryker Corporation has announced its agreement to acquire Inari Medical for $80 per share, marking a notable step forward in the expansion of its vascular portfolio. The acquisition deal, valued at approximately $4 billion, aims to bolster Stryker’s offerings in the treatment of venous diseases, which is a rapidly growing area of healthcare.

Abbott Adjusts 2024 Projections, Fuelled by Medical Device Innovation

6 months ago

Abbott Laboratories recently updated its financial forecasts for the year 2024, indicating a narrowed range that reflects its ongoing commitment to expanding its medical devices segment. The company's revised outlook suggests robust growth driven by an increased demand for its innovative healthcare solutions, particularly in the diagnostic and therapeutic sectors.